BMO Capital weighs in on the FDA rejection of Amgen's (AMGN -1.3%) Xgeva cancer drug, saying...

|About: Amgen Inc. (AMGN)|By:, SA News Editor

BMO Capital weighs in on the FDA rejection of Amgen's (AMGN -1.3%) Xgeva cancer drug, saying that if the firm fails to ultimately win approval for use of the drug it could lose revenue of as much as $1B.